Anaveon AG
Model ANV419 -Systemic no-alpha IL-2 Immunotherapy
FromAnaveon AG
The culmination of our research is ANV419, which is in clinical development. It is a rationally engineered fusion protein that is a stable, antibody-like molecule.
Most popular related searches
- Have better efficacy with excellent selectivity for CD8+ cells
- Result in better safety, no severe toxic events were observed in preclinical trials
- Require less frequent dosing as it is stable for longer in the body